Invest in the best stock opportunities right now and every time.
Start Systematic Stock Investing …in less than a minute.
Lupin and Boehringer lngelheim have entered into licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin's lead MEK inhibitor compound in combination with one of Boehringer lngelheim's innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 899.00 |
Cipla | 953.00 |
Dr. Reddy's Lab | 3913.25 |
Aurobindo Pharma | 559.45 |
Lupin | 683.25 |
View more.. |